InSite Vision to Webcast 2003 Annual Meeting of Stockholders
ALAMEDA, Calif., Dec. 5 /PRNewswire-FirstCall/ -- InSite Vision Incorporated
-- an ophthalmic therapeutics, diagnostics and drug- delivery company -- today
announced that its annual meeting of stockholders will be broadcast live over
the Internet on December 12, 2002 at 1:00 p.m. Eastern Time with management and
the board of directors of InSite Vision. Those listening to the meeting via the
live Internet broadcast will not have the opportunity to ask questions during
the meeting.
What: InSite Vision Annual Meeting of Stockholders When: 1:00 p.m. ET, December 12, 2003 Where: http://www.videonewswire.com/event.asp?id=19195 How: Live over the Internet -- Simply log on to the Web at the
address above.
Contact: Brandi Floberg
Lippert/Heilshorn & Associates, Inc. (310) 691-7100 Following the vote on proxy items, InSite Vision's management will present an
update on the Company, including clinical progress on the ISV-401 and ISV- 403
programs, OcuGene(R) glaucoma genetic test marketing programs, and financing
efforts.
InSite Vision is an ophthalmic products company focused on glaucoma, ocular
infections and retinal diseases. In the area of glaucoma, the Company conducts
genomic research using TIGR and other genes. A portion of this research has
been incorporated into the Company's OcuGene glaucoma genetic test for disease
management, as well as ISV-205, its novel glaucoma therapeutic. ISV-205 uses
InSite Vision's proprietary DuraSite(R) drug- delivery technology, which also is
incorporated into the ocular infection products ISV-401 and ISV-403, and InSite
Vision's retinal disease program. Additional information can be found at
http://www.insitevision.com/ .
If you are unable to participate during the live webcast, the webcast will be
archived beginning approximately two hours following the event for 90 days on
the Company's Web site http://www.insitevision.com/ . To access the replay, go
to the "Investor Relations" section and click on the InSite Vision 2003 Annual
Meeting icon.
(Minimum Requirements to listen to broadcast: Windows Media Player software,
downloadable free from http://www.videonewswire.com/event.asp?id=19195 , and at
least a 28.8Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to .) This press release and the 2003 Annual Meeting of Stockholders webcast may
contain, among other things, certain statements of a forward-looking nature
relating to future events or the future business performance of InSite Vision. Such statements entail a number of risks and uncertainties, including but not
limited to: InSite Vision's immediate need for significant additional funding
to continue its operations; the effects of its expense control activities on its
operations and product development, its ability to obtain regulatory approval
and market acceptance of its products, including ISV-403, OcuGene, ISV-401 and
ISV-205; its ability to maintain and develop additional collaborations and
commercial agreements with corporate partners, including those with respect to
ISV-403, ISV-401 and ISV-205; its reliance on third parties for the development,
marketing and sale of its products; and the initiation and results of
preclinical and clinical studies, its ability to adequately protect its
intellectual property and; determinations by the U.S. Food and Drug
Administration, including those with respect to ISV-403, OcuGene, ISV-401 and
ISV-205. Reference is made to the discussion of risk factors detailed in InSite
Vision's filings with the Securities and Exchange Commission, including its
annual report on Form 10-K for the 2002 fiscal year and Quarterly Report on Form
10-Q for the fiscal quarter ended September 30, 2003. Any projections in this
release are based on limited information currently available to InSite Vision,
which is subject to change. Although any such projections and the factors
influencing them will likely change, InSite Vision undertakes no obligation to
update the information, since InSite Vision may only provide guidance at certain
points during the year. Such information speaks only as of the date of this
release or the date of the telephone conference. Actual events or results could
differ materially and no reader of this release should assume later that the
information provided in the 2003 Annual Meeting of Stockholders webcast is still
valid.
Note to Editors: OcuGene is written with a "small cap" G; if doing so is not
possible, please use an upper case G. InSite Vision Incorporated, InSite
Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other
trademarks that may be mentioned in this release are the intellectual property
of their respective owners.
For further information, please contact: S. Kumar Chandrasekaran, CEO, or
Sandra Heine, Director of Finance, both of InSite Vision Incorporated,
+1-510-865-8800; or investors, Bruce Voss, , or Jody Cain, , both of
Lippert/Heilshorn & Associates, Inc., for InSite Vision Incorporated,
+1-310-691-7100; or media, Chenoa Taitt, , or Michael Hopkins, , both of
Lippert/Heilshorn & Associates, Inc., +1-212-838-3777, for InSite Vision
Incorporated. http://www.videonewswire.com/event.asp?id=19195DATASOURCE: InSite Vision
Incorporated CONTACT: S. Kumar Chandrasekaran, CEO, or Sandra Heine, Director of Finance, both of InSite Vision Incorporated, +1-510-865-8800; or investors, Bruce Voss, , or Jody Cain, , both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for InSite Vision Incorporated; or media, Chenoa Taitt, , or Michael Hopkins, , both of Lippert/Heilshorn & Associates, Inc., +1-212-838-3777, for InSite Vision Incorporated Web site: http://www.lhai.com/ Web site: http://www.insitevision.com/
|